Novel Agent Fails to Show Sufficient Activity in Recurrent Osteosarcoma
November 14, 2017

The GPNMB-targeted agent known as glembatumumab vedotin was reasonably well tolerated and showed some activity in a phase II study of recurrent/refractory osteosarcoma, but this activity was not enough to continue the drug’s evaluation in this setting based on the study protocol.

Aftercare in Sarcoma Should Incorporate Time- and Risk-Adjusted Strategies
November 12, 2017

An analysis of more than 800 patients found that the one-size-fits-all approach to “aftercare” for localized soft-tissue sarcoma is misguided. Local recurrence and distant metastasis occur in a non-constant fashion in the years after treatment, and a time- and risk-adapted strategy for aftercare is warranted.

Regional Hyperthermia Plus Chemo Improves Outcomes in Soft-Tissue Sarcoma
November 11, 2017

Treatment with hyperthermia improved survival when added to neoadjuvant chemotherapy for patients with localized high-risk soft-tissue sarcoma.